{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/prescribing-information/calcium-channel-blockers/","result":{"pageContext":{"chapter":{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers","depth":2,"htmlHeader":"<!-- begin field 3b4b86bf-7aae-4d73-a74e-a71600db3920 --><h2>Calcium-channel blockers</h2><!-- end field 3b4b86bf-7aae-4d73-a74e-a71600db3920 -->","summary":"","htmlStringContent":"<!-- begin item a53f3bb0-21ee-4749-9773-a71600db39c4 --><!-- end item a53f3bb0-21ee-4749-9773-a71600db39c4 -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1818367c-36b4-513c-95ad-767ed866dbc2","slug":"choice-of-calcium-channel-blocker","fullItemName":"Choice of calcium-channel blocker","depth":3,"htmlHeader":"<!-- begin field f3d5fc5c-31af-48f0-9f80-a71a00cc035a --><h3>Which calcium-channel blockers are recommended?</h3><!-- end field f3d5fc5c-31af-48f0-9f80-a71a00cc035a -->","summary":"","htmlStringContent":"<!-- begin item 1200bdef-e9b3-4f5a-83b0-a71a00cc042a --><!-- begin field b559ab66-1000-4fb2-99cd-a71a00cc035a --><ul><li>The decision to use either a rate-limiting or a dihydropyridine calcium-channel blocker depends on the person's co-morbidities and other drugs the person is taking.</li><li>Where possible, prescribe a drug that is taken only once a day and prescribe non-proprietary drugs where these are appropriate and minimise cost.</li><li><strong>Dihydropyridine calcium-channel blockers</strong><ul><li>The choice of dihydropyridine calcium-channel blocker depends on local recommendations. For people with hypertension alone, amlodipine may be preferred on the basis of cost.</li><li>For people with hypertension and angina, amlodipine, felodipine, and modified-release nifedipine may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>.</li></ul></li><li>For people with hypertension and Type 2 diabetes, amlodipine, felodipine, and once-daily modified-release nifedipine may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li></ul></li></ul></li><li><strong>Rate-limiting calcium-channel blockers</strong><ul><li>Once-daily formulations of diltiazem are recommended — there is little difference in cost compared with twice-daily formulations, and once-daily dosage regimens might be more convenient for some people.</li><li>Once-daily formulations of verapamil are recommended. Non-proprietary verapamil needs to be taken twice daily. Modified-release verapamil can be given once daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">National Clinical Guideline Centre, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field b559ab66-1000-4fb2-99cd-a71a00cc035a --><!-- end item 1200bdef-e9b3-4f5a-83b0-a71a00cc042a -->","subChapters":[]},{"id":"a911fcaf-acb0-5e15-9902-9364738d89b9","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d37845ee-5609-4d6c-a5be-a71a00cc1a4b --><h3>Contraindications and cautions</h3><!-- end field d37845ee-5609-4d6c-a5be-a71a00cc1a4b -->","summary":"","htmlStringContent":"<!-- begin item 6107dd22-8a6b-47fd-b345-a71a00cc1b95 --><!-- begin field 75d5ea0b-6f7e-40e6-80c6-a71a00cc1a4b --><p><strong>Contraindications and cautions associated with use of calcium channel blockers include:</strong></p><ul><li><strong>Heart failure</strong><ul><li>All calcium-channel blockers can precipitate heart failure in predisposed people.</li><li>Verapamil and diltiazem should not be used in people with heart failure.</li><li>Although dihydropyridines rarely aggravate heart failure (any negative inotropic effect is offset by a reduction in left ventricular work), they should not be initiated in people with uncontrolled heart failure. Amlodipine may be used cautiously in stable heart failure.</li></ul></li><li><strong>Cardiac outflow obstruction</strong> (for example significant aortic stenosis or obstructive hypertrophic cardiomyopathy) — vasodilatation may result in reduced cardiac output.</li><li><strong>Second degree atrioventricular block</strong> — verapamil and diltiazem may induce complete atrioventricular block.</li><li><strong>Hepatic impairment</strong><ul><li>The half-life of diltiazem and verapamil is prolonged in people with impaired liver function. Low doses should be used.</li><li>Modified-release nifedipine should be avoided in people with hepatic impairment because the duration of effect is considerably prolonged.</li></ul></li><li><strong>Renal impairment </strong>— although diltiazem and verapamil are extensively metabolized in the liver, the manufacturers recommend a dose reduction in people with renal impairment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016m</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 75d5ea0b-6f7e-40e6-80c6-a71a00cc1a4b --><!-- end item 6107dd22-8a6b-47fd-b345-a71a00cc1b95 -->","subChapters":[]},{"id":"8aff9284-71b9-510c-8f6f-42acacd8070b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8b32a416-a4fa-4a61-a583-a71a00cc551c --><h3>Adverse effects</h3><!-- end field 8b32a416-a4fa-4a61-a583-a71a00cc551c -->","summary":"","htmlStringContent":"<!-- begin item 8efc938a-ce53-431f-bf3e-a71a00cc5601 --><!-- begin field b4952d2c-c86a-4668-b6be-a71a00cc551c --><ul><li>Abdominal pain and nausea may result from use of amlodipine and felodipine.</li><li>Atrioventricular block may be caused by use of diltiazem and verapamil.</li><li>Bradycardia may result from taking diltiazem or verapamil.</li><li>Constipation may result from use of nifedipine, verapamil, diltiazem, and verapamil.</li><li>Dizziness and somnolence may be caused by amlodipine, especially at the beginning of treatment.</li><li>Erythema, pruritis, and urticaria may result from use of diltiazem and verapamil.</li><li>Vasodilatory adverse effects (flushing, headaches, ankle swelling) are less common with rate-limiting calcium-channel blockers than with dihydropyridine calcium-channel blockers, and often improve with continued use. Diuretics should not be prescribed to relieve ankle swelling.</li><li>Gingival hyperplasia is rarely observed — drug withdrawal usually results in disappearance of the symptoms.</li><li>Palpitations may result from use of calcium channel blockers.</li><li>Vertigo and tinnitus may result from use of verapamil.</li><li>Vomiting and diarrhoea may result from use of diltiazem and verapamil.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field b4952d2c-c86a-4668-b6be-a71a00cc551c --><!-- end item 8efc938a-ce53-431f-bf3e-a71a00cc5601 -->","subChapters":[]},{"id":"cda62dd7-cf8b-59a2-9242-23e47685a2bf","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 60e6a378-e8f5-444e-a92e-a71a00cc6fcb --><h3>Drug interactions</h3><!-- end field 60e6a378-e8f5-444e-a92e-a71a00cc6fcb -->","summary":"","htmlStringContent":"<!-- begin item b3a56768-c9c0-4b7d-a96a-a71a00cc7107 --><!-- begin field 27d2ac39-99cc-48bb-9fec-a71a00cc6fcb --><p><strong>Drug interactions with calcium channel blockers include:</strong></p><ul><li><strong>Alpha-blockers, angiotensin-converting enzyme-inhibitors, angiotensin-II receptor blockers, antipsychotics, anxiolytics and hypnotics, baclofen, clonidine, co-beneldopa, co-careldopa, diazoxide, diuretics, hydralazine, levodopa, methyldopa, minoxidil, monoamine oxidase inhibitors, moxisylyte, moxonidine, nitrates,</strong> <strong>sodium nitroprusside, and tizanidine </strong>— enhanced antihypertensive effect.</li><li><strong>Amiodarone </strong>—<strong> </strong>increased risk of bradycardia, AV block and myocardial depression when given with diltiazem or verapamil.</li><li><strong>Aminophylline and theophylline</strong> — plasma concentrations increased by concurrent use of calcium channel blockers.</li><li><strong>Antidepressants</strong> — tricyclic antidepressants, mirtazapine, and trazodone should be prescribed with caution in people taking calcium-channel blockers, as there is an increased risk of postural hypotension.</li><li><strong>Atazanavir</strong> — plasma concentration of diltiazem increased with concurrent use (reduce dose of diltiazem).</li><li><strong>Avanafil, Bosutinib, ciclosporin</strong> — concurrent use with diltiazem or verapamil may lead to increased plasma concentrations of these drugs. Dose alterations may be required.</li><li><strong>Carbamazepine</strong> — concurrent use with diltiazem or verapamil may lead to enhanced effects of carbamazepine. Dose alterations may be required.</li><li><strong>Colchicine</strong> — diltiazem and verapamil possibly increase risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).</li><li><strong>Beta-blockers </strong>— verapamil contraindicated (risk of reduced cardiac output and heart failure); diltiazem with caution (diltiazem has a smaller negative inotropic effect than verapamil – monitor the person's pulse and blood pressure carefully due to the risk of bradycardia); hypotensive effect enhanced with all calcium channel blockers.</li><li><strong>Clarithromycin, erythromycin</strong> — metabolism of calcium-channel blockers possibly inhibited leading to increased risk of side-effects.</li><li><strong>Dabigatran and lenalidomide </strong>— verapamil possibly increases plasma concentrations of these drugs.</li><li><strong>Digoxin</strong> — concurrent use with diltiazem or verapamil may lead to increased plasma concentrations of digoxin. Monitor for signs of toxicity and consider monitoring plasma digoxin levels.</li><li><strong>Disopyramide</strong> — concurrent use with verapamil may lead to increased risk of myocardial depression and asystole.</li><li><strong>Dronedarone, flecainide</strong> — increased risk of bradycardia and myocardial depression when diltiazem or verapamil given with these drugs.</li><li><strong>Enzyme-inducing drugs</strong> (such as carbamazepine) — increase the elimination of dihydropyridines, resulting in a reduced hypotensive effect. Monitor the clinical response to the dihydropyridine and increase its dose if necessary. Consider reducing the dihydropyridine dose if the enzyme-inducing drug is discontinued.</li><li><strong>mTOR inhibitors (sirolimus, temsirolimus, everolimus)</strong> — amlodipine and verapamil are CYP3A inhibitors, concomitant use with these drugs may increase their levels.</li><li><strong>Fingolimod</strong> — possible increased risk of bradycardia when diltiazem or verapamil is given with fingolimod.</li><li><strong>Fosphenytoin</strong> — diltiazem increases plasma concentration of fosphenytoin but also effect of diltiazem reduced.</li><li><strong>Ibrutinib, ivabradine, lomitapide, lurasidone, olaparib, sirolimus and tacrolimus</strong> — diltiazem and verapamil possibly increase the plasma concentrations of these drugs. Reduce dose of ibrutinib, avoid concomitant use with ivabradine, lomitapide, and olaparib.</li><li><strong>Mefloquine</strong> — possible increased risk of bradycardia during concurrent use with calcium channel blockers.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — hypotensive effect of calcium channel blockers antagonised.</li><li><strong>Phenobarbital, primidone</strong> — effects of calcium-channel blockers probably reduced with concurrent use. </li><li><strong>Phenytoin</strong> — diltiazem increases plasma concentration of phenytoin, effect of diltiazem also reduced.</li><li><strong>Rifampicin</strong> — plasma concentration of diltiazem and verapamil decreased with concurrent use.</li><li><strong>Ritonavir</strong> — plasma concentration of calcium-channel blockers possibly increased with concurrent use.</li><li><strong>Sirolimus</strong> — plasma concentration of both drugs increased when verapamil is given with sirolimus.</li><li><strong>Statins</strong> — possible increased risk of myopathy when diltiazem or verapamil given with simvastatin, plasma concentration of verapamil increased by atorvastatin, also possible increased risk of myopathy (consider reducing dose of atorvastatin).</li><li><strong>St John's Wort </strong>— plasma concentration of verapamil significantly reduced by St John's wort.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2018</a>]</p><!-- end field 27d2ac39-99cc-48bb-9fec-a71a00cc6fcb --><!-- end item b3a56768-c9c0-4b7d-a96a-a71a00cc7107 -->","subChapters":[]},{"id":"276e4ea5-9b68-5485-ab75-5610c4a5e176","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 18ef482e-f121-43ff-9c0c-a71a00cc2dec --><h3>Dose and titration</h3><!-- end field 18ef482e-f121-43ff-9c0c-a71a00cc2dec -->","summary":"","htmlStringContent":"<!-- begin item d5687cd2-a45e-4dba-8c90-a71a00cc2f3b --><!-- begin field e8ef71de-e0d7-442e-88e3-a71a00cc2dec --><ul><li>Start with a low dose of calcium-channel blocker and titrate upwards (if necessary) at intervals of 4 weeks until the target blood pressure has been achieved.</li><li>Measure blood pressure 4 weeks after each dose change.</li><li>Dose for rate-limiting calcium-channel blockers<ul><li>Once-daily modified-release diltiazem:<ul><li>Note: recommended doses and dosing intervals differ depending on the preparation prescribed. Some modified release preparations are not appropriate for initial dose titration. For more information, see the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"47c5892c-0bee-43b9-91eb-a8f7015d0f2f\">British National Formulary</a>.</li><li>Elderly people and those with hepatic or renal impairment, the recommended starting dose is usually 120 mg daily.</li><li>For others, the standard starting doses are 180–240 mg daily.</li><li>Maximum doses are generally 240–360 mg daily.</li></ul></li><li>Modified-release verapamil (non-proprietary)<ul><li>The standard starting dose is 240 mg once a day. For people new to verapamil therapy, consider halving the initial dose to 120 mg.</li><li>The maximum dose is 240 mg twice a day (doses spaced by an interval of 12 hours).</li></ul></li></ul></li><li>Doses for dihydropyridine calcium-channel blockers are shown in the table.</li></ul><p><strong>Table 3. </strong>Usual starting, maintenance, and maximum doses of dihydropyridine calcium-channel blockers for hypertension.</p><table><thead><tr><th scope=\"col\">Calcium-channel blocker</th><th scope=\"col\">Usual starting doses</th><th scope=\"col\">Usual maintenance dose</th><th scope=\"col\">Maximum dose</th></tr></thead><tbody><tr><td>Amlodipine</td><td>5 mg once a day</td><td>5-10 mg once a day</td><td>10 mg once a day</td></tr><tr><td>Felodipine</td><td>5 mg once a day*</td><td>5-10 mg once a day</td><td>20 mg once a day</td></tr><tr><td>Nifedipine</td><td>20-30 mg once a day</td><td>30-90 mg once a day</td><td>90 mg once a day</td></tr><tr><td colspan=\"4\">* A lower starting dose of 2.5 mg is required for elderly people.</td></tr><tr><td colspan=\"4\"><strong>Information from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</td></tr></tbody></table><!-- end field e8ef71de-e0d7-442e-88e3-a71a00cc2dec --><!-- end item d5687cd2-a45e-4dba-8c90-a71a00cc2f3b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}